Division of Endocrinology and Metabolism, Department of Internal Medicine, The University of Michigan, and The Veterans Administration Health System, Ann Arbor, Michigan 48105
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
Aldosterone is the most important circulating mineralocorticoid. It is secreted by the zona glomerulosa of the adrenal gland and plays a major role in sodium and potassium metabolism by binding to epithelial mineralocorticoid receptors (MR) in the renal collecting duct, promoting sodium resorption and potassium excretion. The action of aldosterone on its classic target epithelia has been extensively studied, and many of the signaling events that mediate its effects have been described. Recently, there has been increased interest in aldosterone actions on the cardiovascular system, which are mediated through nonclassical actions. These include local tissue production, nongenomic actions, and effects on nonepithelial targets. In this review article, we focus on the effects of aldosterone in nonepithelial tissues that are mediated through MR, especially cardiovascular effects.
aldosterone; cardiac fibrosis; hypertension; blood pressure; central nervous system
![]() |
ALDOSTERONE ACTIONS |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
Mineralocorticoid receptors.
Most of the aldosterone actions that have been described in
nonepithelial tissues appear to be mediated through the interaction of
aldosterone and mineralocorticoid receptors (MR). Therefore, to
explore these actions of aldosterone, one needs to understand the
aldosterone-MR interaction and the localization of MR in target organs.
MR belong to a superfamily of steroid/thyroid/retinoid/orphan receptors
and operate as ligand-activated transcription factors to regulate gene
expression. MR are most closely related to other steroid receptors,
notably the glucocorticoid receptor (GR). Human MR are 984-amino acid
proteins that have been cloned and sequenced (2); they
share high homology with GR, 57% homology in the ligand binding domain
and 94% in the DNA bonding domain (23). It has been
demonstrated and confirmed that MR bind to both aldosterone and
cortisol with almost indistinguishable high affinity in vitro (38, 44), whereas in vivo MR clearly have specificity for aldosterone, despite the fact that glucocorticoids are present at much
higher concentrations in plasma. The factors that enhance specific
binding of MR to aldosterone are 1) binding of plasma glucocorticoids to glucocorticoid-binding protein and albumin, allowing
only a small amount (~10%) of the unbound hormone to freely cross
cellular membranes (22); 2) presence in target cells of 11-hydroxysteroid dehydrogenase type 2 (11
HSD2), an enzyme that metabolizes active forms of glucocorticoids into inactive forms in aldosterone target tissues (24); 3)
discrimination of aldosterone from glucocorticoid by the MR. The
dissociation of aldosterone from MR is five times slower than that of
glucocorticoids, despite their similar affinity constants
(40). The role of 11
HSD2 has received the most
attention; 11
HSD2 converts cortisol and corticosterone to inactive
forms that cannot bind to MR. In contrast, aldosterone is not a
substrate for 11
HSD2, because its 11-OH group is protected by
cyclization. Structural or functional defects of 11
HSD2 are known to
cause the syndrome of apparent mineralocorticoid excess
(23), and inhibition of 11
HSD2 with glycyrrhetinic acid mimics the syndrome (58). Signs and symptoms of
mineralocorticoid excess in these patients indicate that functioning
11
HSD2 is necessary to prevent glucocorticoid binding and activation
of MR.
Target cells. MR have been identified in nonepithelial as well as epithelial cells. The characteristics and properties of MR in these tissues are similar (36, 38, 39); however, MR-mediated effects appear to be different in the different tissues. In epithelial cells, aldosterone acts to enhance sodium reabsorption by activating apical epithelial Na+ channels (ENaC) and the basolateral Na+ pump. The earliest mineralocorticoid effect is an increase in the activity of ENaC; however, ENaC mRNA and protein levels do not increase. A recent report by Chen et al. (13) indicates that aldosterone induces expression of sgk, a serine-threonine kinase that in turn directly stimulates ENaC activity. These effects on the renal collecting duct mediate a major regulatory site for control of body sodium and water, as well as blood pressure regulation (see review in Ref. 4). In contrast, aldosterone effects in the heart and brain appear to be unrelated to epithelial sodium transport. In the heart, aldosterone promotes cardiac hypertrophy and fibrosis unrelated to hemodynamic effects (7). In the brain, aldosterone affects neural regulation of blood pressure, salt appetite, volume regulation, and sympathetic outflow (16).
The presence of MR in the cardiovascular system has been confirmed at the mRNA and protein levels in animal models and in humans. Lombes et al. (41) showed that, in rabbit, MR are present in myocytes, endocardium, vascular endothelium, and vascular smooth muscle cells (SMC) of large vessels. The study also showed that these MR have identical characteristics to the MR of renal origin. Human cardiac tissue biopsy also demonstrated MR expression in myocardium and endocardium by use of in situ hybridization and immunohistochemistry (39). As we have noted, 11Nongenomic effects. Recent reports have indicated that some effects of aldosterone are not mediated through binding to MR (15, 63, 68, 69). These actions have been termed "nongenomic" to distinguish them from the "genomic" effects that occur as a result of gene transcription after activation of nuclear receptors. In many cell lines, aldosterone induces a rapid (<10-min) increase of inositol triphosphate and calcium, repression of protein kinase C activity, and activation of the Na+-K+ pump. These actions have been observed in human mononuclear leukocytes, vascular SMC, and rat cardiomyocytes. Specific antagonists of MR and inhibition of transcription or protein synthesis did not block these actions (14, review in 15, 67). A double-blind placebo-controlled randomized study in humans showed that, after intravenous administration of a large dose of aldosterone, there were significant changes in systemic vascular resistance, cardiac output, and cardiac index compared with the placebo group. The effects appeared at 3 min and dissipated within 10 min, a time course that is too rapid to be explained by genomic effects (53, 69). The effects of mineralocorticoid antagonists on these actions have not been studied in humans.
In summary, most of the known actions of aldosterone in both epithelial and nonepithelial cells are mediated by activation of MR, which in turn regulate gene expression and transcription. MR have high homology with other steroid nuclear receptors, and the selectivity of MR for aldosterone is enhanced by several mechanisms, the most important of which is the presence of 11 ![]() |
DIRECT ALDOSTERONE ACTIONS ON THE CARDIOVASCULAR SYSTEM |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
Hypertrophy and fibrosis. Aldosterone has been shown to induce ventricular hypertrophy and fibrosis in cardiac interstitial and perivascular tissues. Myocardial fibrosis does not occur in cardiac hypertrophy unless there is concurrent activation of the renin-angiotensin-aldosterone system. Thus chronic anemia, arteriovenous fistula, and atrial septal defect lead to hypertrophy without fibrosis. This observation led Brilla et al. (7) to explore the role of aldosterone in the genesis of cardiac fibrosis. They compared different experimental hypertensive rat models: elevated angiotensin II and aldosterone induced by a renovascular lesion, normal angiotensin II and aldosterone in infrarenal aorta binding, isolated elevated aldosterone by minipumps plus high salt intake, and control. The results showed ventricular hypertrophy with myocardial fibrosis in the models with elevated aldosterone levels and with high, normal, and suppressed angiotensin II levels, suggesting that elevation in circulating angiotensin II alone was not the decisive mediator of the fibrous tissue response. They concluded that elevated aldosterone was important in the regulation of collagen synthesis within the cardiac interstitium and in the adventitia of intramyocardial coronary arteries (7). Subsequently, the same laboratory demonstrated that administration of an aldosterone antagonist, spironolactone, at a dose that had no antihypertensive effect, could prevent cardiac fibrosis (6). Recently, Schlaich et al. (52) confirmed by use of M-mode echocardiography a correlation between plasma levels of aldosterone and cardiac left ventricular mass in human subjects. This correlation was not related to differences in blood pressure. A recent prospective clinical trial has shown that treatment with spironolactone significantly reduced morbidity and mortality among patients with severe heart failure. Blood pressure was not affected by spironolactone treatment, suggesting that endogenous aldosterone has direct deleterious effects on the cardiovascular system in these patients (46).
The cellular mechanisms by which aldosterone induces fibrosis are still under investigation. Initial studies from Weber's laboratory reported that aldosterone stimulated transcription of collagen I mRNA and increased levels of collagen I synthesis in rat cardiac fibroblasts (5, 11). Robert et al. (48) also demonstrated an increase in cardiac type I and type III collagen mRNA in rats made hypertensive with aldosterone and salt treatment. However, other laboratories (21, 37) could not confirm these findings. They proposed that aldosterone does not influence fibroblast collagen synthesis directly but increases endothelin receptor number, which leads to increased collagen synthesis (21). These studies are difficult to interpret, because the effect of aldosterone to increase cardiac fibrosis occurs over a long period of time and may not be detectable in an in vitro culture system. This topic is reviewed in depth by Slight et al. (56).Plasminogen activator inhibitor-1. Aldosterone may have a role in the regulation of plasminogen activator inhibitor-1 (PAI-1) (8, 9). Although aldosterone had no direct effect on PAI-1 activity in vitro, it did enhance the stimulatory effect of angiotensin II on PAI-1 activity. In a rat model of radiation-induced glomerulosclerosis, spironolactone decreased the degree of sclerosis and the level of PAI-1 mRNA expression (10).
Effects on vascular tone.
Aldosterone also modulates vascular tone, although the exact mechanisms
remain to be elucidated. Possible mechanisms include increased
vasoconstrictive effects of catecholamines through decreased tissue
catecholamine uptake (65), impaired vasodilatation in response to acetylcholine (60), upregulation of
-adrenergic (34) and angiotensin II (50,
51) receptors, and a direct aldosterone effect, possibly through
nongenomic mechanisms. There is evidence that aldosterone also affects
vascular SMC via MR, causing transmembrane influx of sodium and
potentiating angiotensin II-induced leucine incorporation into SMC in
vitro (31). These mechanisms may be involved in
hypertrophy of SMC. Aldosterone administration, in nonpressor doses,
augmented neointimal thickening in the rabbit iliac artery after
balloon-induced vascular injury. Conversely, spironolactone
administration reduced the thickening compared with both aldosterone
and control groups (61). Wang et al.
(65) demonstrated that perfusion of the carotid
sinus with aldosterone reduced baroreceptor discharge in the dog,
and a similar finding has been reported in humans (59).
Cerebrovascular effects. Studies in stroke-prone spontaneously hypertensive rats have indicated a possible role for aldosterone in vascular remodeling and stroke. Spironolactone treatment in these animals did not reduce blood pressure but did prevent spontaneous cerebral infarction (49). Captopril, an angiotensin-converting enzyme inhibitor, also prevented cerebral infarction, but coadministration of aldosterone reversed the captopril effect (42, 57). Dorrance et al. (19) reported that spironolactone treatment reduced the size of cerebral infarcts induced by middle cerebral artery ligation. These authors also found that mineralocorticoid treatment increased vascular expression of receptors for epidermal growth factor (EGF). They proposed that aldosterone increases vascular remodeling by increasing vascular EGF receptor activity (19).
Local biosynthesis.
In addition to effects of circulating mineralocorticoids on the heart,
local biosynthesis of aldosterone has recently been reported and may
have physiological or pathophysiological importance. In the isolated
rat heart, Silvestre et al. (54) used quantitative reverse
transcription-polymerase chain reaction (RT-PCR) analysis to document
mRNA expression of both aldosterone synthase (CYP11B2) and
11-hydroxylase (CYP11B1), crucial enzymes in the pathway of
mineralocorticoid synthesis. They used celite column chromatography coupled to radioimmunoassay to measure tissue levels of aldosterone. The cardiac aldosterone synthesis pathway is responsive to a
low-sodium/high-potassium diet and to angiotensin II in a manner
similar to that of the adrenal cortex. Silvestre et al. demonstrated
that cardiac aldosterone levels are many times higher than those in
plasma, suggesting that locally synthesized aldosterone within the
heart may be important for local paracrine or autocrine function. The
physiological role of this local system remains to be explored.
![]() |
CENTRALLY MEDIATED ALDOSTERONE ACTIONS |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
The classic GR is widely distributed in brain in both neurons and
glial cells, with a high density in the hippocampus and other parts of
the limbic system (25, 62). MR are less prevalent in the
central nervous system (CNS), and their location is predominantly limited to neurons of the hippocampus and lateral septum
(47). Unlike MR targets in epithelial tissue or the
cardiovascular system, the brain lacks significant 11HSD2 activity;
therefore, brain MR are not protected from glucocorticoid binding, and
MR can bind to both mineralocorticoids and glucocorticoids. Thus, it
appears likely that glucocorticoids are the primary ligand for most
brain MR. Reul and de Kloet (47) showed that >80% of MR
in the brain are occupied by endogenous hormones under basal resting
conditions. In contrast, brain GR are significantly occupied only when
circulating glucocorticoid levels are high. De Kloet and colleagues
(16, 17) postulated that MR mediate tonic actions of
corticosteroids involved in maintenance of homeostasis. In contrast,
the GR is likely to be important in dynamic responses and the
restoration of homeostasis. Corticosteroids in brain appear to be
involved in the regulation of several physiological systems: learning
and memory (16), neuroendocrine
hypothalmic-pituitary-adrenal axis regulation (17),
autonomic function, control of sodium homeostasis, and blood pressure
regulation. Most of these effects are mediated through activation of
MR, possibly by interaction between MR and either glucocorticoids or
mineralocorticoids. In this review, we will focus on the role of
MR-mediated effects in the CNS on blood pressure control.
Despite almost negligible levels of 11HSD2 activity in the brain,
there is evidence that certain areas contain MR that bind preferentially to mineralocorticoids. This has been demonstrated in the
anterior hypothalamus, hippocampus, anterior pituitary, and some nuclei
in the brain stem (1, 3, 18, 20). The MR in the
hypothalamus and circumventricular organs are involved in the
regulation of blood pressure and sodium homeostasis.
Aldosterone acts directly in the CNS to increase blood pressure. This action is separate from its systemic effects and is not associated with changes in fluid and electrolyte balance, salt appetite, or vascular reactivity. Gomez-Sanchez and colleagues (27-29) have extensively explored this issue in a series of experiments comparing the effects of subcutaneous and intracerebroventricular administration of corticosteroid agonists and antagonists in rats. Continuous intracerebroventricular infusion of aldosterone produced a significant increase in blood pressure that was blocked by concomitant intracerebroventricular infusion of MR antagonists, either prorenone (27) or RU-28318 (28). The hypertension induced by the continuous intracerebroventricular infusion of aldosterone was dose responsive and independent of changes in renal sodium handling (45); blood pressure increased in sodium-deplete as well as sodium-replete dogs and rats (12, 35). The doses of steroids given intracerebroventricularly were small and did not cause changes in blood pressure when given subcutaneously. Similar findings were also reported in dogs receiving centrally administered aldosterone (35). Gomez-Sanchez et al. (29) also demonstrated that corticosterone antagonized the pressor effect of centrally administered aldosterone in a dose-dependent fashion if it was coinfused intracerebroventricularly with aldosterone. Bilateral adrenalectomy in rats prevented the pressor effect of intracerebroventricular aldosterone, and the effect was restored by administration of physiological replacement doses of corticosterone (29). Central infusion of a selective MR antagonist, RU-28318, diminished the hypertensive effect of subcutaneous aldosterone infusion (28, 32), and this amount of intracerebroventricular RU-28318 was less than that required to inhibit the increased appetite for saline associated with excess systemic mineralocorticoids (27, 29, 43).
Deoxycorticosterone acetate (DOCA) in combination with dietary salt is commonly used to induce mineralocorticoid hypertension. In this experimental model, attenuation of the baroreflex response can usually be detected before elevation of blood pressure occurs. In DOCA-salt-treated rats, intracerebroventricular infusion of RU-28318 normalized the baroreflex, reduced sympathetic tone, and prevented hypertension (33). The prehypertensive stage of intracerebroventricular aldosterone-induced hypertension, in contrast to that of systemic mineralocorticoid excess states, is not associated with a decrease in baroreceptor reactivity, nor is there an increase in vascular reactivity to the intravenous infusion of angiotensin II, norepinephrine, or arginine vasopressin (32, 33).
These results, taken together, indicate that direct CNS effects of aldosterone play a significant role in the pressor effects that occur when steroids are administered systemically.
A recent study by Gomez-Sanchez et al. (26) suggested that the brain has the capability to produce aldosterone. RT-PCR/Southern blot hybridization demonstrated aldosterone synthase in the hypothalamus, hippocampus, amygdala, cerebrum, and cerebellum of rat brain. Incubation of [3H]DOCA, a substrate for aldosterone synthase, with minced brain from hippocampus, hypothalamus, and cerebellum, yielded [3H]aldosterone. In contrast, incubation of minced brain with aldosterone synthesis inhibitors, either cortisol or metyrapone, inhibited aldosterone production.
In conclusion, it is clear that aldosterone has important physiological and pathophysiological effects on nonepithelial tissues. In the cardiovascular system it promotes ventricular hypertrophy and interstitial cardiac and perivascular fibrosis. It may also increase PAI-1 activity. It probably plays an important role in the pathophysiology of heart failure. In the CNS, aldosterone acts to increase blood pressure and sympathetic activity. The importance of locally produced aldosterone in these tissues and the role of nongenomic actions of aldosterone remain to be determined.
![]() |
FOOTNOTES |
---|
Address for reprint requests and other correspondence: R. J. Grekin, VA Medical Center, 2215 Fuller Road, Ann Arbor, MI 48105.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
1.
Anderson, NS, III,
and
Fanestil DD.
Corticoid receptors in rat brain: evidence for an aldosterone receptor.
Endocrinology
98:
676-684,
1976[Abstract].
2.
Arriza, JL,
Weinberger C,
Cerelli G,
Glaser TM,
Handelin BL,
Housman DE,
and
Evans RM.
Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor.
Science
237:
268-275,
1987[ISI][Medline].
3.
Birmingham, MK,
Stumpf WE,
and
Sar M.
Nuclear localization of aldosterone in rat brain cells assessed by autoradiography.
Experientia
35:
1240-1241,
1979[ISI][Medline].
4.
Bonvalet, JP.
Regulation of sodium transport by steroid hormones.
Kidney Int Suppl
65:
S49-S56,
1998[Medline].
5.
Brilla, CG,
and
Maisch B.
Regulation of the structural remodelling of the myocardium: from hypertrophy to heart failure.
Eur Heart J
15:
45-52,
1994[Abstract].
6.
Brilla, CG,
Matsubara LS,
and
Weber KT.
Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension.
Am J Cardiol
71:
12A-16A,
1993[Medline].
7.
Brilla, CG,
Pick R,
Tan LB,
Janicki JS,
and
Weber KT.
Remodeling of the rat right and left ventricles in experimental hypertension.
Circ Res
67:
1355-1364,
1990[Abstract].
8.
Brown, NJ,
Agirbasli MA,
Williams GH,
Litchfield WR,
and
Vaughan DE.
Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1.
Hypertension
32:
965-971,
1998
9.
Brown, NJ,
Kim KS,
Chen YQ,
Blevins LS,
Nadeau JH,
Meranze SG,
and
Vaughan DE.
Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production.
J Clin Endocrinol Metab
85:
336-344,
2000
10.
Brown, NJ,
Nakamura S,
Ma L,
Nakamura I,
Donnert E,
Freeman M,
Vaughan DE,
and
Fogo AB.
Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo.
Kidney Int
58:
1219-1227,
2000[ISI][Medline].
11.
Chapman, D,
Weber KT,
and
Eghbali M.
Regulation of fibrillar collagen types I and III and basement membrane type IV collagen gene expression in pressure overloaded rat myocardium.
Circ Res
67:
787-794,
1990[Abstract].
12.
Chen, M,
Lee J,
and
Malvin RL.
Central administration of aldosterone increases blood pressure in rats.
Clin Exp Hypertens
11:
459-472,
1989.
13.
Chen, SY,
Bhargava A,
Mastroberardino L,
Meijer OC,
Wang J,
Buse P,
Firestone GL,
Verrey F,
and
Pearce D.
Epithelial sodium channel regulated by aldosterone-induced protein sgk.
Proc Natl Acad Sci USA
96:
2514-2519,
1999
14.
Christ, M,
Douwes K,
Eisen C,
Bechtner G,
Theisen K,
and
Wehling M.
Rapid effects of aldosterone on sodium transport in vascular smooth muscle cells.
Hypertension
25:
117-123,
1995
15.
Christ, M,
and
Wehling M.
Rapid actions of aldosterone: lymphocytes, vascular smooth muscle and endothelial cells.
Steroids
64:
35-41,
1999[ISI][Medline].
16.
De Kloet, ER,
Van Acker SA,
Sibug RM,
Oitzl MS,
Meijer OC,
Rahmouni K,
and
de Jong W.
Brain mineralocorticoid receptors and centrally regulated functions.
Kidney Int
57:
1329-1336,
2000[ISI][Medline].
17.
De Kloet, ER,
Vreugdenhil E,
Oitzl MS,
and
Joels M.
Brain corticosteroid receptor balance in health and disease.
Endocr Rev
19:
269-301,
1998
18.
De Nicola, AF,
Tornello S,
Weisenberg L,
Fridman O,
and
Birmingham MK.
Uptake and binding of [3H]aldosterone by the anterior pituitary and brain regions in adrenalectomized rats.
Horm Metab Res
13:
103-106,
1981[ISI][Medline].
19.
Dorrance, AM,
Grekin R,
and
Webb R.
Aldosterone antagonism reduces cerebral infarct size in normotensive rats.
J Hypertens
18:
S84,
2000[ISI].
20.
Ermisch, A,
and
Ruhle HJ.
Autoradiographic demonstration of aldosterone-concentrating neuron populations in rat brain.
Brain Res
147:
154-158,
1978[ISI][Medline].
21.
Fullerton, MJ,
and
Funder JW.
Aldosterone and cardiac fibrosis: in vitro studies.
Cardiovasc Res
28:
1863-1867,
1994[ISI][Medline].
22.
Funder, JW,
Feldman D,
and
Edelman IS.
The roles of plasma binding and receptor specificity in the mineralocorticoid action of aldosterone.
Endocrinology
92:
994-1004,
1973[ISI][Medline].
23.
Funder, JW,
Krozowski Z,
Myles K,
Sato A,
Sheppard KE,
and
Young M.
Mineralocorticoid receptors, salt, and hypertension.
Recent Prog Horm Res
52:
247-262,
1997[ISI][Medline].
24.
Funder, JW,
Pearce PT,
Smith R,
and
Smith AI.
Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated.
Science
242:
583-585,
1988[ISI][Medline].
25.
Fuxe, K,
Wikstrom AC,
Okret S,
Agnati LF,
Harfstrand A,
Yu ZY,
Granholm L,
Zoli M,
Vale W,
and
Gustafsson JA.
Mapping of glucocorticoid receptor immunoreactive neurons in the rat tel- and diencephalon using a monoclonal antibody against rat liver glucocorticoid receptor.
Endocrinology
117:
1803-1812,
1985[Abstract].
26.
Gomez-Sanchez, CE,
Zhou MY,
Cozza EN,
Morita H,
Foecking MF,
and
Gomez-Sanchez EP.
Aldosterone biosynthesis in the rat brain.
Endocrinology
138:
3369-3373,
1997
27.
Gomez-Sanchez, EP.
Intracerebroventricular infusion of aldosterone induces hypertension in rats.
Endocrinology
118:
819-823,
1986[Abstract].
28.
Gomez-Sanchez, EP,
Fort CM,
and
Gomez-Sanchez CE.
Intracerebroventricular infusion of RU28318 blocks aldosterone-salt hypertension.
Am J Physiol Endocrinol Metab
258:
E482-E484,
1990
29.
Gomez-Sanchez, EP,
Venkataraman MT,
Thwaites D,
and
Fort C.
ICV infusion of corticosterone antagonizes ICV-aldosterone hypertension.
Am J Physiol Endocrinol Metab
258:
E649-E653,
1990
30.
Hatakeyama, H,
Inaba S,
Takeda R,
and
Miyamori I.
11-hydroxysteroid dehydrogenase in human vascular cells.
Kidney Int
57:
1352-1357,
2000[ISI][Medline].
31.
Hatakeyama, H,
Miyamori I,
Fujita T,
Takeda Y,
Takeda R,
and
Yamamoto H.
Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells.
J Biol Chem
269:
24316-24320,
1994
32.
Janiak, P,
and
Brody MJ.
Central interactions between aldosterone and vasopressin on cardiovascular system.
Am J Physiol Regulatory Integrative Comp Physiol
255:
R166-R173,
1988
33.
Janiak, PC,
Lewis SJ,
and
Brody MJ.
Role of central mineralocorticoid binding sites in development of hypertension.
Am J Physiol Regulatory Integrative Comp Physiol
259:
R1025-R1034,
1990
34.
Jazayeri, A,
and
Meyer WJ, III.
Mineralocorticoid-induced increase in beta-adrenergic receptors of cultured rat arterial smooth muscle cells.
J Steroid Biochem
33:
987-991,
1989[ISI][Medline].
35.
Kageyama, Y,
and
Bravo EL.
Hypertensive mechanisms associated with centrally administered aldosterone in dogs.
Hypertension
11:
750-753,
1988[Abstract].
36.
Kenouch, S,
Lombes M,
Delahaye F,
Eugene E,
Bonvalet JP,
and
Farman N.
Human skin as target for aldosterone: coexpression of mineralocorticoid receptors and 11 beta-hydroxysteroid dehydrogenase.
J Clin Endocrinol Metab
79:
1334-1341,
1994[Abstract].
37.
Kohler, E,
Bertschin S,
Woodtli T,
Resink T,
and
Erne P.
Does aldosterone-induced cardiac fibrosis involve direct effects on cardiac fibroblasts?
J Vasc Res
33:
315-326,
1996[ISI][Medline].
38.
Krozowski, ZS,
and
Funder JW.
Renal mineralocorticoid receptors and hippocampal corticosterone-binding species have identical intrinsic steroid specificity.
Proc Natl Acad Sci USA
80:
6056-6060,
1983[Abstract].
39.
Lombes, M,
Alfaidy N,
Eugene E,
Lessana A,
Farman N,
and
Bonvalet JP.
Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart.
Circulation
92:
175-182,
1995
40.
Lombes, M,
Kenouch S,
Souque A,
Farman N,
and
Rafestin-Oblin ME.
The mineralocorticoid receptor discriminates aldosterone from glucocorticoids independently of the 11 beta-hydroxysteroid dehydrogenase.
Endocrinology
135:
834-840,
1994[Abstract].
41.
Lombes, M,
Oblin ME,
Gasc JM,
Baulieu EE,
Farman N,
and
Bonvalet JP.
Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor.
Circ Res
71:
503-510,
1992[Abstract].
42.
MacLeod, AB,
Vasdev S,
and
Smeda JS.
The role of blood pressure and aldosterone in the production of hemorrhagic stroke in captopril-treated hypertensive rats.
Stroke
28:
1821-1829,
1997
43.
McEwen, BS,
Lambdin LT,
Rainbow TC,
and
De Nicola AF.
Aldosterone effects on salt appetite in adrenalectomized rats.
Neuroendocrinology
43:
38-43,
1986[ISI][Medline].
44.
Myles, K,
and
Funder JW.
Type I (mineralocorticoid) receptors in the guinea pig.
Am J Physiol Endocrinol Metab
267:
E268-E272,
1994
45.
Peysner, K,
Henry CA,
and
Malvin RL.
Central infusion of aldosterone increases blood pressure by mechanisms independent of Na retention.
Clin Exp Hypertens
12:
399-414,
1990.
46.
Pitt, B,
Zannad F,
Remme WJ,
Cody R,
Castaigne A,
Perez A,
Palensky J,
and
Wittes J.
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
New Engl J Med
341:
709-717,
1999
47.
Reul, JM,
and
de Kloet ER.
Two receptor systems for corticosterone in rat brain: microdistribution and differential occupation.
Endocrinology
117:
2505-2511,
1985[Abstract].
48.
Robert, V,
Silvestre JS,
Charlemagne D,
Sabri A,
Trouve P,
Wassef M,
Swynghedauw B,
and
Delcayre C.
Biological determinants of aldosterone-induced cardiac fibrosis in rats.
Hypertension
26:
971-978,
1995
49.
Rocha, R,
Chander PN,
Khanna K,
Zuckerman A,
and
Stier CT, Jr.
Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats.
Hypertension
31:
451-458,
1998
50.
Schiffrin, EL,
Franks DJ,
and
Gutkowska J.
Effect of aldosterone on vascular angiotensin II receptors in the rat.
Can J Physiol Pharmacol
63:
1522-1527,
1985[ISI][Medline].
51.
Schiffrin, EL,
Gutkowska J,
and
Genest J.
Effect of angiotensin II and deoxycorticosterone infusion on vascular angiotensin II receptors in rats.
Am J Physiol Heart Circ Physiol
246:
H608-H614,
1984
52.
Schlaich, MP,
Schobel HP,
Hilgers K,
and
Schmieder RE.
Impact of aldosterone on left ventricular structure and function in young normotensive and mildly hypertensive subjects.
Am J Cardiol
85:
1199-1206,
2000[ISI][Medline].
53.
Schmidt, BM,
Montealegre A,
Janson CP,
Martin N,
Stein-Kemmesies C,
Scherhag A,
Feuring M,
Christ M,
and
Wehling M.
Short term cardiovascular effects of aldosterone in healthy male volunteers.
J Clin Endocrinol Metab
84:
3528-3533,
1999
54.
Silvestre, JS,
Robert V,
Heymes C,
Aupetit-Faisant B,
Mouas C,
Moalic JM,
Swynghedauw B,
and
Delcayre C.
Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation.
J Biol Chem
273:
4883-4891,
1998
55.
Slight, SH,
Ganjam VK,
Gomez-Sanchez CE,
Zhou MY,
and
Weber KT.
High affinity NAD(+)-dependent 11 beta-hydroxysteroid dehydrogenase in the human heart.
J Mol Cell Cardiol
28:
781-787,
1996[ISI][Medline].
56.
Slight, SH,
Joseph J,
Ganjam VK,
and
Weber KT.
Extra-adrenal mineralocorticoids and cardiovascular tissue.
J Mol Cell Cardiol
31:
1175-1184,
1999[ISI][Medline].
57.
Smeda, J,
Vasdev S,
and
King SR.
Effect of poststroke captopril treatment on mortality associated with hemorrhagic stroke in stroke-prone rats.
J Pharmacol Exp Ther
291:
569-575,
1999
58.
Stewart, PM,
Wallace AM,
Valentino R,
Burt D,
Shackleton CH,
and
Edwards CR.
Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age.
Lancet
2:
821-824,
1987[ISI][Medline].
59.
Struthers, AD.
Aldosterone escape during ACE inhibitor therapy in chronic heart failure.
Eur Heart J
16:
103-106,
1995[ISI][Medline].
60.
Taddei, S,
Virdis A,
Mattei P,
and
Salvetti A.
Vasodilation to acetylcholine in primary and secondary forms of human hypertension.
Hypertension
21:
929-933,
1993[Abstract].
61.
Van Belle, E,
Bauters C,
Wernert N,
Hamon M,
McFadden EP,
Racadot A,
Dupuis B,
Lablanche JM,
and
Bertrand ME.
Neointimal thickening after balloon denudation is enhanced by aldosterone and inhibited by spironolactone, an aldosterone antagonist.
Cardiovas Res
29:
27-32,
1995[ISI][Medline].
62.
Van Steensel, B,
van Binnendijk EP,
Hornsby CD,
van der Voort HT,
Krozowski ZS,
de Kloet ER,
and
van Driel R.
Partial colocalization of glucocorticoid and mineralocorticoid receptors in discrete compartments in nuclei of rat hippocampus neurons.
J Cell Sci
109:
787-792,
1996
63.
Verrey, F.
Early aldosterone effects.
Exp Nephrol
6:
294-301,
1998[ISI][Medline].
64.
Walker, BR,
Yau JL,
Brett LP,
Seckl JR,
Monder C,
Williams BC,
and
Edwards CR.
11 Beta-hydroxysteroid dehydrogenase in vascular smooth muscle and heart: implications for cardiovascular responses to glucocorticoids.
Endocrinology
129:
3305-3312,
1991[Abstract].
65.
Wang, W,
McClain JM,
and
Zucker IH.
Aldosterone reduces baroreceptor discharge in the dog.
Hypertension
19:
270-277,
1992[Abstract].
66.
Weber, MA,
and
Purdy RE.
Catecholamine-mediated constrictor effects of aldosterone on vascular smooth muscle.
Life Sci
30:
2009-2017,
1982[ISI][Medline].
67.
Wehling, M,
Kasmayr J,
and
Theisen K.
Rapid effects of mineralocorticoids on sodium-proton exchanger: genomic or nongenomic pathway?
Am J Physiol Endocrinol Metab
260:
E719-E726,
1991
68.
Wehling, M,
Neylon CB,
Fullerton M,
Bobik A,
and
Funder JW.
Nongenomic effects of aldosterone on intracellular Ca2+ in vascular smooth muscle cells.
Circ Res
76:
973-979,
1995
69.
Wehling, M,
Spes CH,
Win N,
Janson CP,
Schmidt BM,
Theisen K,
and
Christ M.
Rapid cardiovascular action of aldosterone in man.
J Clin Endocrinol Metab
83:
3517-3522,
1998